Marc RendellMarc Rendell, M.D. is Professor and Director of the Diabetes Center at Creighton University in Omaha, Nebraska and Medical Director of the Rose Salter Medical Research Foundation in Baltimore, Maryland. His principal basic research interests are in microvascular blood flow changes in diabetes and in wound healing.

He has a large clinical research program, having studied most of the new hypoglycemic agents developed in the past decade. He also has a strong interest in diabetic neuropathy and has evolved new techniques for assessment of this condition. In addition, he has participated im numerous studies of new anti-hypertensive and hypolipidemic drugs. He was the lead investigator for the study of sildenafil in diabetic patients. He has served as consultant to Otsuka Pharmaceutical Inc in the successful development leading to FDA approval of cilostazol for the treatment of claudication.
There is a strong working relationship between the Creighton Diabetes Center and the Creighton Cardiac Center, which has a special expertise in non-invasive cardiac imaging procedures. There are 19 cardiologists in the Creighton Cardiac Center. The Center has a staff of 170. There are over 3500 new patient visits and 11,000 outpatient visits annually.

The Creighton Diabetes Center has a 1500 square foot facility with seven exam rooms. There are five study coordinators, including a Nurse Practioner, all with significant clinical trials experience. In the last year, there have been more than 4000 patient visits to the facility, 75% representing patients participating in research protocols.

Contact

Creighton Diabetes Center
601 N 30th St. Suite 6715
Omaha, NE 68131
Phone: (402) 280-4319
Fax: (402) 280-5245